

FMHL/SEC/SE/BM/JAN'18
January 23, 2018

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code: 523696

Sub: Outcome of the Board Meeting

Dear Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. January 23, 2018, *inter-alia*, considered and approved the Un-audited Financial Results for the quarter and period ended on December 31, 2017.

Please find enclosed 'Un-audited Financial Results' and 'Limited Review Report' thereon along with a copy of the press release being issued in this regard.

Further, please note that the Board of Directors have approved the appointment of Mr. Shashank Porwal as the Company Secretary and Compliance Officer of the Company with immediate effect and have also designated him as one of the Key Managerial Personnel. Mr. Porwal is an associate member of the Institute of Company Secretaries of India (ACS: 51957) and a Commerce Graduate.

The Board Meeting commenced at 11:30 a.m. and concluded at 01:00 p.m.

This is for your information and records please.

Yours faithfully
For **Fortis Malar Hospitals Limited**


Daljit Singh
Director
DIN: 00135414



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF FORTIS MALAR HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **FORTIS MALAR HOSPITALS LIMITED** ("the Company"), for the Quarter and nine months ended December 31, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Geetha Suryanarayanan
Partner
(Membership No. 29519)

Chennai, January 23, 2018

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

(Rs. in lakhs except EPS)

No.	Particulars	Quarter ended			Period ended		Year ended
		December 31, 2017	September 30, 2017	December 31, 2016	December 31, 2017	December 31, 2016	March 31, 2017
		(Unaudited)			(Unaudited)		(Audited)
1	Income						
	a) Revenue from operations	3,770.25	3,727.03	3,624.45	10,881.52	10,570.49	14,055.99
	b) Other Income	216.30	193.15	184.05	594.78	569.91	756.26
	Total Income	3,986.55	3,920.18	3,808.50	11,476.30	11,140.40	14,812.25
2	Expenses						
	a) Purchase of Medical Consumables and Drugs	885.11	770.91	760.50	2,394.90	2,334.63	2,941.59
	b) Changes In Inventories of Medical Consumables and Drugs	(0.42)	7.15	54.74	(74.73)	(29.28)	29.92
	c) Employee Benefits Expense	548.51	539.40	515.21	1,625.93	1,469.36	1,978.52
	d) Finance Costs	11.08	8.95	11.46	31.25	30.37	45.81
	e) Professional Charges to Doctors	1,032.32	1,090.61	1,098.89	3,186.65	3,167.74	4,236.35
	f) Clinical Establishment Fees	534.04	530.80	507.61	1,566.84	1,499.97	2,003.17
	g) Depreciation and Amortization expenses	106.16	106.01	100.98	312.97	294.61	394.09
	h) Other Expenses	734.81	678.85	638.69	2,142.07	2,003.99	2,778.97
	Total Expenses	3,851.61	3,732.68	3,688.08	11,185.08	10,771.39	14,408.42
3	Profit from Ordinary Activities before Tax (1 - 2)	134.94	187.50	120.42	290.42	369.01	403.83
4	Tax expense						
	- Current Tax / MAT	90.14	84.23	19.96	194.01	182.39	182.39
	- Deferred Tax	(45.53)	(22.13)	14.80	(97.99)	(61.87)	(60.59)
	Total tax expense	44.61	62.10	34.76	96.02	120.52	121.80
5	Net Profit from Ordinary Activities After Tax (3 - 4)	90.33	125.40	85.66	194.40	248.49	282.03
6	Other Comprehensive Income						
	Items that will not be reclassified subsequently to the statement of profit and loss:						
	(a) Remeasurements of the defined benefit plans	14.74	6.79	(6.55)	14.42	(20.78)	(35.92)
	(b) Income tax relating to items that will not be reclassified to profit or loss	(4.87)	(2.24)	-	(4.77)	-	11.88
	Other Comprehensive Income	9.87	4.55	(6.55)	9.65	(20.78)	(24.04)
7	Total Comprehensive Income for the period (5+6)	100.20	129.95	79.11	204.05	227.71	257.99
8	Paid up Equity Share Capital (Face Value Rs.10 each)	1,869.95	1,869.95	1,867.95	1,869.95	1,867.95	1,867.95
9	Reserves excluding Revaluation Reserves						7,959.97
10	Earnings Per Share (EPS) of Rs. 10 each (not annualised) (In Rs.)						
	- Basic	0.48	0.67	0.47	1.04	1.22	1.51
	- Diluted	0.48	0.67	0.47	1.03	1.22	1.50



[Handwritten signature]



FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)
Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali-160062
Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002
Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

Notes:

- 1 The above unaudited financial results have been reviewed by the Audit and Risk Management Committee, approved and taken on record by the Board of Directors in their meetings held on January 23, 2018. The unaudited results for the quarter ended December 31, 2017 has been subject to limited review by the statutory auditors of the Company.
- 2 The Company operates in a single segment (i.e.) Healthcare Services and hence, does not have any additional disclosures to be made under IND AS 108 - Operating Segments.
- 3 The Board of Directors of the Company at its meeting held on August 19, 2016 approved the proposal for the sale of its hospital business by way of a slump sale to Fortis Healthcare Limited (FHL) pursuant to a composite scheme of Arrangement and Amalgamation (the Scheme) between the Company, FHL and SRL Limited ("SRL"). Further, pursuant to the said Scheme, the diagnostic business of FHL (including investments held in SRL) shall get demerged into the Company *in lieu* of equity shares to be issued by the Company to the shareholders of FHL. The demerger shall be followed by SRL being merged with the Company as an integral part of the same Scheme and shares of the Company to be issued to the eligible shareholders of SRL. The Board of Directors of the Company, on December 14, 2017 by way of Resolution Passed by Circulation, approved the extension of the Long Stop Date to June 30, 2018 as per the Clause 61 of the Scheme. The next hearing before NCLT is scheduled on Jan 30, 2018. The Scheme is subject to various judicial/regulatory and other required approvals. Pending such approvals, no effect of the proposed Scheme has been given in the Financial Results.
- 4 Previous period figures have been regrouped / reclassified, where necessary, to conform with the current period presentation.



By Order of the Board
For and on behalf of Board of Directors

Dajit Singh
Director
DIN No.00135414

Place: Chennai
Date : January 23, 2018